Abstract
Amrubicin, a completely synthetic 9‐aminoanthracycline derivative, was previously shown to have potent antitumor activities against various human tumor xenografts. In this study, the in vitro activities of amrubicin and its major metabolite, amrubicinol, were examined using 17 human tumor cell lines. Amrubicinol was 5 to 54 times more potent than amrubicin, and as potent as doxorubicin, in inhibiting the growth of the cells following 3‐day continuous drug exposure. Amrubicinol closely resembled doxorubicin in its profile of activities on the 17 human tumor cell lines. Cells were incubated with the drugs for 1 h, and the intracellular drug concentration and cell growth inhibition after 3 days were determined. Amrubicinol attained similar intracellular concentrations at lower medium concentrations compared to amrubicin, and the intracellular concentration of amrubicinol necessary to produce 50% cell growth inhibition was 3 to 8 times lower than that of amrubicin in 4 cell lines tested. Amrubicinol has a higher activity level inside the cells than does amrubicin. When cells were incubated with amrubicin for 5 h, a substantial amount of amrubicinol, more than 9% of that of amrubicin, was found in cells in 4 of the 8 cell lines tested. Amrubicinol may contribute to the in vitro growth‐inhibitory effect of amrubicin on these cells. The results suggest that amrubicinol plays an important role in the in vivo antitumor effect of amrubicin as an active metabolite.
Keywords: Anthracycline, Amrubicin, SM‐5887, Metabolism
Full Text
The Full Text of this article is available as a PDF (96.1 KB).
REFERENCES
- 1. ) Ishizumi , K. , Ohashi , N. and Tanno , N.Stereospecific total synthesis of 9‐aminoanthracyclines: (+)‐9‐amino‐9‐deoxydaunomycin and related compound . J. Org. Chem. , 52 , 4477 – 4485 ( 1987. ). [Google Scholar]
- 2. ) Morisada , S. , Yanagi , Y. , Noguchi , T. , Kashiwazaki , Y. and Fukui , M.Antitumor activities of a novel 9‐aminoanthracycline SM‐5887 against mouse experimental tumors and human tumor xenografts . Jpn. J. Cancer Res. , 80 , 69 – 76 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. ) Takigawa , N. , Ohnoshi , T. , Ueoka , H. , Kiura , K. and Kimura , I.Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines . Acta Med. Okayama , 46 , 249 – 256 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Bachur , N. R.Anthracycline antibiotic pharmacology and metabolism . Cancer Treat. Rep. , 63 , 817 – 820 ( 1979. ). [PubMed] [Google Scholar]
- 5. ) Robert , J. , Bui , N. B. and Vrignaud , P.Pharmacokinetics of doxorubicin in sarcoma patients . Eur. J. Clin. Pharmacol. , 31 , 695 – 700 ( 1987. ). [DOI] [PubMed] [Google Scholar]
- 6. ) Mross , K. , Maessen , P. , Van Der Vijgh , W. J. , Gall , F. H. , Boven , E. and Pinedo , H. M.Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans . J. Clin. Oncol. , 6 , 517 – 526 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 7. ) Zanette , L. , Zucchetti , M. , Freshi , A. , Erranti , D. , Tirrelli , U. and D'Incalci , M.Pharmacokinetics of 4‐demethoxy‐daunorubicin in cancer patients . Cancer Chemother. Pharmacol. , 25 , 445 – 448 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 8. ) Reid , J. M. , Pendergrass , T. W. , Krailo , M. D. , Hammond , G. D. and Ames , M. M.Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Children's Cancer Study Group report . Cancer Res. , 50 , 6525 – 6528 ( 1990. ). [PubMed] [Google Scholar]
- 9. ) Broggini , M. , Sommacampagna , B. , Paolini , A. , Dolfini , E. and Donelli , M. G.Comparative metabolism of daunorubicin and 4‐demethoxydaunorubicin in mice and rabbits . Cancer Treat. Rep. , 70 , 697 – 702 ( 1986. ). [PubMed] [Google Scholar]
- 10. ) Cusack , B. J. , Young , S. P. , Driskell , J. and Olson , R. D.Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rat . Cancer Chemother. Pharmacol. , 32 , 53 – 58 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 11. ) Cusack , B. J. , Young , S. P. and Olson , R. D.Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat . Cancer Chemother. Pharmacol. , 35 , 213 – 218 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 12. ) Le Bot , M. A. , Begue , J. M. , Kernaleguen , D. , Robert , J. , Ratanasavanh , D. , Airiau , J. , Riche , C. and Guillouzo , A.Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin, and idarubicin in cultured human and rat hepatocytes . Biochem. Pharmacol. , 37 , 3877 – 3888 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 13. ) Geetha , V. and Ahmed , N. K.Uptake and metabolism of daunorubicin by human myelocytic cells . Cancer Chemother. Pharmacol. , 15 , 35 – 39 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 14. ) Chevillard , S. , Vielh , P. , Bastian , G. and Coppey , J.Adriamycin uptake and metabolism in organotypic culture of A549 human adenocarcinoma cells according to the exposure time . J. Cancer Res. Clin. Oncol. , 116 , 633 – 638 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. ) Le Bot , M. A. , Glaise , D. , Kernaleguen , D. , Ratanasavanh , D. , Carlhant , D. , Riche , C. and Guillouzo , A.Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells . Pharmacol. Res. , 24 , 243 – 252 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 16. ) Kuffel , M. J. , Reid , J. M. and Ames , M. M.Anthracyclines and their C‐13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture . Cancer Chemother. Pharmacol. , 30 , 51 – 57 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 17. ) Ferrazzi , E. , Woynarowski , J. M. , Arakali , A. , Brenner , D. E. and Beerman , T. A.DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics doxorubicin and idarubicin . Cancer Commun. , 3 , 173 – 180 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 18. ) Dessypris , E. N. , Brenner , D. E. , Baer , M. R. and Hande , K. R.Uptake and intracellular distribution of doxorubicin metabolites in B‐lymphocytes of chronic lymphocytic leukemia . Cancer Res. , 48 , 503 – 506 ( 1988. ). [PubMed] [Google Scholar]
- 19. ) Ozols , R. F. , Willson , J. K. V. , Weltz , M. D. , Grotzinger , K. R. , Myers , C. E. and Young , R. C.Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites . Cancer Res. , 40 , 4109 – 4112 ( 1980. ). [PubMed] [Google Scholar]
- 20. ) Limonta , M. , Biondi , A. , Giudici , G. , Specchia , G. , Catapano , C. , Masera , G. , Barbui , T. and D'Incalci , M.Cytotoxicity and DNA damage caused by 4‐demethoxy‐daunorubicin and its metabolite 4‐demethoxy‐13‐hydroxy‐daunorubicin in human acute myeloid leukemia cells . Cancer Chemother. Pharmacol. , 26 , 340 – 342 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 21. ) Noguchi , T. , Ichii , S. , Morisada , S. , Yamaoka , T. and Yanagi , Y.In vivo efficacy and tumor‐selective metabolism of amrubicin to its active metabolite . Jpn. J. Cancer Res. , 89 , 1055 – 1060 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. ) Matsushita , Y. , Iguchi , H. , Kiyosaki , T. , Tone , H. , Ishikura , T. , Takeuchi , T. and Umezawa , H.A high performance liquid chromatographic method of analysis of 4′‐O tetrahydropyranyladriamycin and its metabolites in biological samples . J. Antibiot. , 36 , 880 – 886 ( 1983. ). [DOI] [PubMed] [Google Scholar]
- 23. ) Schott , S. and Robert , J.Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin‐sensitive and ‐resistant rat glioblastoma cells . Biochem. Pharmacol. , 38 , 167 – 172 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 24. ) Gonzalez , B. , Akman , S. , Doroshow , J. , Rivera , H. , Kaplan , W. D. and Forrest , G. L.Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells . Cancer Res. , 55 , 4646 – 4650 ( 1995. ). [PubMed] [Google Scholar]